Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 mars 2025 17h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Participate at Upcoming Investor Conferences
24 févr. 2025 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in...
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
20 févr. 2025 16h01 HE
|
Travere Therapeutics, Inc.
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full...
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
13 févr. 2025 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 févr. 2025 17h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
11 févr. 2025 07h01 HE
|
Travere Therapeutics, Inc.
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25
Travere Therapeutics Provides Corporate Update and 2025 Outlook
13 janv. 2025 07h00 HE
|
Travere Therapeutics, Inc.
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA...
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual...
Travere Therapeutics to Present at Upcoming Investor Conferences
25 nov. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 nov. 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted...